Table 2.
Primary/Secondary and Adherence Outcome Comparisons at Baseline (B) and 10-Week Post FU (P)
| Measure | Group Assignment
|
P-value | |
|---|---|---|---|
| Placebo (n=60) | Omega3 (n=62) | ||
|
| |||
| Primary | |||
| BDI-II | |||
| Pre | 29.0 ± 9.2 | 28.1 ± 8.7 | .59 |
| Post | 15.0 ± 9.7 | 15.9 ± 10.2 | .64 |
| HAM-D-17 | |||
| Pre | 19.2 ± 5.1 | 21.2 ± 5.6 | .04 |
| Post | 9.1 ± 6.7 | 9.7 ± 6.5 | .61 |
| Secondary | |||
| BAI | |||
| Pre | 15.2 ± 9.9 | 16.1 ± 8.8 | .59 |
| Post | 11.0 ± 10.1 | 10.9 ± 9.2 | .96 |
| Mean treatment adherence (% days pill removed) | |||
| Omega-3/Placebo | 97.3 ± 3.1 | 97.4 ± 4.3 | .97 |
| Sertraline | 98.5 ± 2.6 | 98.6 ± 3.1 | .88 |
| Omega-Index (% EPA + DHA in RBC) | |||
| Pre (n=121) | 4.6 ± 1.4 | 4.6 ± 1.5 | .95 |
| Post (n=114) | 4.6 ± 1.2 (n=55) | 7.6 ± 1.8 (n=59) | <.0001 |
Continuous outcomes are reported as mean ± SD.
Keywords: BDI-II = Beck Depression Inventory II; HAM-D-17 = Hamilton Rating Scale for Depression; BAI = Beck Anxiety Inventory; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; RBC = red blood cells